Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its ...

Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of ...

Advancing investigational pre-clinical research of APL-9099 3, a potential one-time neonatal Fc receptor (FcRn) treatment ...

Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 ...

About one third of lung transplant recipients have a genetic variant that makes them more likely to develop chronic lung ...

Impacts of biological amendments, including waste-derived amendments that underpin soil health and agricultural ...

On November 2, 2025, the research group led by Dr. Zeng Ling from Army Medical University systematically elucidated the molecular mechanisms, ...

Analyzing data from airborne campaigns, the study reveals that older shallow-water platforms in Angola emit more methane than ...

In a phase three, double blind, placebo controlled trial, pegcetacoplan significantly reduced proteinuria compared with ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...